AI Article Synopsis
- Visceral leishmaniasis (VL) is a severe disease that impacts millions in developing countries and can be fatal without treatment.
- Current treatments are insufficient, creating a critical need for better medications.
- This paper details the discovery and optimization of a specific chemical structure that proved effective in oral doses within a mouse model of VL.
Article Abstract
Visceral leishmaniasis (VL) affects millions of people across the world, largely in developing nations. It is fatal if left untreated and the current treatments are inadequate. As such, there is an urgent need for new, improved medicines. In this paper, we describe the identification of a 6-amino--(piperidin-4-yl)-1-pyrazolo[3,4-]pyrimidine scaffold and its optimization to give compounds which showed efficacy when orally dosed in a mouse model of VL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651859 | PMC |
| http://dx.doi.org/10.1039/d0md00203h | DOI Listing |
Publication Analysis
Top Keywords
visceral leishmaniasis
8
identification 6-amino-1-pyrazolo[34-]pyrimidines
4
6-amino-1-pyrazolo[34-]pyrimidines efficacy
4
efficacy visceral
4
leishmaniasis visceral
4
leishmaniasis millions
4
millions people
4
people developing
4
developing nations
4
nations fatal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!